News

Indian Pharma Targets Booming $145 Billion US Oncology Market with Generic Cancer Drugs

Indian pharmaceutical companies are making aggressive strides into the booming US oncology market, leveraging FDA approvals, government incentives, and global demand for affordable cancer treatments.

• By Pooja Chaturvedi Sah
• New Delhi
• Apr 18, 2025

News

Indian pharmaceutical companies are accelerating their entry into the fast-growing US oncology generics market, currently valued at $145 billion and expanding at a rapid 11% annual rate. With a flurry of FDA approvals and government-backed manufacturing initiatives, Indian drugmakers are sharpening their focus on high-value cancer drugs, biosimilars, and complex generics to solidify their global footprint—particularly in the lucrative American market.

India’s Strategic Entry into a High-Growth Sector

Indian drug manufacturers are gaining momentum in the US oncology market, which is projected to grow from $145 billion in 2024 to approximately $417 billion by 2034. Several Indian firms, including Cipla, Biocon Biologics, and Zydus Lifesciences, have recently secured USFDA approvals for generic oncology drugs—signaling a significant increase in the presence of complex generics and biosimilars in the US.

Industry analysts say this shift marks India's transformation from being a supplier of commoditized generics to a key player in specialty and high-margin therapies such as cancer treatment.

Government-Backed Investment Bolsters Sector Growth

The Indian government’s Production Linked Incentive (PLI) Scheme—launched in 2021 with a budget of ₹15,000 crore—has played a pivotal role in energizing the sector. The initiative targets the production of critical medicines such as anti-cancer drugs and biopharmaceuticals to reduce import reliance and scale up exports.

As of late 2024, actual investments under the scheme had surpassed expectations, reaching ₹4,253.92 crore, exceeding the committed ₹3,938.57 crore. Major infrastructure projects include a Penicillin G facility in Andhra Pradesh and a Clavulanic Acid plant in Himachal Pradesh—both designed to enhance self-reliance in key raw materials.

Foreign Direct Investment Signals Strong Global Confidence

Between April and December 2024, India’s pharmaceutical and medical device sector drew ₹11,888 crore in foreign direct investment. By FY25, an additional ₹7,246 crore was greenlit across 13 brownfield projects, raising the cumulative FDI inflow to over ₹19,134 crore. Analysts view this as a clear sign of global investor confidence in India’s pharma capabilities and long-term prospects.

Tapping the US Market: Opportunities and Headwinds

Indian pharma companies are capitalizing on the US market’s push to diversify supply chains away from China. Their competitive advantage—affordable production, regulatory know-how, and a strong base of USFDA-compliant facilities—is helping them fill critical gaps in the oncology supply chain.

However, challenges persist. Companies face ongoing pricing pressures, regulatory scrutiny from the FDA, and potential litigation over patent infringement. Still, the consistent stream of USFDA approvals signals resilience and readiness to meet the global demand for affordable cancer treatment.

Expanding Domestic Oncology Market Mirrors Global Trends

Back home, the Indian oncology market is also poised for significant expansion. It is projected to grow from $1.98 billion in 2025 to $2.62 billion by 2029, at a CAGR of 7.18%. Another forecast by Technavio expects a surge of $2.02 billion at an even steeper CAGR of 19.8% between 2024 and 2029.

This growth is driven by rising cancer incidence—expected to reach 1.6 million new cases with 700,000 deaths annually by 2025—and a growing need for affordable diagnostics and treatments. Indian startups and institutions are increasingly investing in R&D to innovate cost-effective cancer diagnostics and therapies.

India’s Expanding Global Pharma Footprint

India holds the distinction of having the largest number of USFDA-compliant pharma plants outside the US—over 2,000 WHO-GMP-certified facilities across more than 150 countries. With over 10,500 manufacturing units and a robust contract research, development, and manufacturing (CRDMO) ecosystem, India is emerging as a central node in the global pharma supply chain. Macquarie projects the Indian CRDMO industry will double to ₹1.21 lakh crore (US$14 billion) by 2028.

Experts believe that with continued policy support, infrastructure expansion, and a relentless push toward affordability and innovation, India can play a transformative role in making cancer care more accessible—not just domestically, but around the world.